Today before the opening bell,
International Stem Cell Corp., a California-based biotechnology company
developing novel stem cell based therapies and biomedical products, announced
that it will be giving a platform presentation on its preclinical studies in
Parkinson’s at the 2015 American Academy of Neurology Annual Meeting in
Washington, DC. Ruslan Semechkin, Ph.D., ISCO’s chief scientific officer, will
discuss the data at the “Parkinson’s Disease” scientific session (s48.007), on
Thursday, April 23rd at 4:45 pm in a talk entitled “Neural Stem Cell Based
Therapy for Parkinson’s Disease.”
“These animal studies strongly suggest
that the transplantation of human parthenogenetic neural stem cells (hpNSCs),
for the treatment of Parkinson’s will be efficacious, safe and well tolerated,”
stated Ruslan Semechkin, Ph.D. “The data further elucidate our platform and
help solidify expectations for our planned Phase 1/2a studies in humans.”
The data presented are from two safety
studies, where human parthenogenetic neural stem cells (hpNSC) were
transplanted into the brains of healthy animals, and a proof-of-principle study
where the cells were transplanted into animals with induced Parkinson’s disease
symptoms. The studies show that hpNSCs migrated to the injured brain area,
increased dopamine levels, protected and recovered neurons and improved the
motor function. Additionally, at the conclusion of the twelve month non-human
primate safety study, no evidence of teratoma formation or ectopic tissue was
found in any animals that received the human cell transplants.
ISCO has built a comprehensive
preclinical safety dataset from a series of GLP and non-GLP studies on hpNSC.
The Company has submitted a CTX application to the Australian regulatory
authorities and plans to begin the phase 1/2a clinical study within the next
few months.
For those not familiar with them, hpNSCs
are a novel therapeutic cellular product derived from International Stem Cell
Corporation’s proprietary human pluripotent stem cells. Neural stem cells work
to repair the brain in several ways. The cells are attracted to the site of
injury and in response to signals released by the damaged tissue release a
range of molecules that reduce inflammation and trigger the recovery process.
Neural stem cells also have the ability to generate new cells to replace those
that are either dead or dying enabling the formation of new tissue. In this way
the hpNSCs act as coordinators of all the various activities necessary to
recover brain function.
To learn more about International Stem
Cell Corp. and its technologies, visit www.internationalstemcell.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment